Changeflow GovPing Pharma & Drug Safety Triacetyl-3-hydroxyphenyladenosine patent for f...
Routine Notice Added

Triacetyl-3-hydroxyphenyladenosine patent for fatty liver

Email

Summary

Triacetyl-3-hydroxyphenyladenosine patent for fatty liver

Source document (simplified)

← EPO Patent Bulletin

TRIACETYL-3-HYDROXYPHENYLADENOSINE AND APPLICATION IN PREPARING PHARMACEUTICAL DRUG FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE

Publication EP3398604A1 Kind: A1 Mar 25, 2026

Applicants

Beijing Gushen Life Health Technology Co., Ltd., Institute of Materia Medica, Chinese Academy
of Medical Sciences

Inventors

ZHU, Haibo, SHI, Huijie

IPC Classifications

A61K 31/7076 20060101AFI20190513BHEP A61P 1/16 20060101ALI20190513BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.